Recludix Pharma To Participate In Two Investor Conferences In December
( MENAFN - GlobeNewsWire - Nasdaq) SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in discovery of inhibitors of challenging targets for inflammatory disease, today announced ...
Knowridge1d
Research finds a big cause of autoimmune diseases
Scientists at the Garvan Institute of Medical Research have uncovered a connection between certain genetic variations and the ...
Cancer Therapy Advisor3d
Will ACT001 Move the Needle in DIPG?
The combination of ACT001 and radiotherapy elicited responses and was considered well tolerated in a phase 2 trial of pediatric patients with newly diagnosed DIPG.
AAP on MSN4d
'Invisible' cancer revealed to body in new research
Researchers have unlocked a key in a person's immune response that could halt the spread of cancer the body cannot see.